“Worryingly, OSA does not affect all people equally. Women with mild OSA have more symptoms but are less likely to be diagnosed and treated, while Indigenous Australians are more than twice as likely to have OSA and associated diseases compared to their non-Indigenous counterparts.”
One barrier for diagnoses is access to specialised equipment and sleep centres. To address this, Dr Farnham’s team is investigating the potential of a simple blood test for identifying certain chemicals produced by the brain as a diagnostic tool.
Current OSA therapies also require expensive equipment, which disadvantages vulnerable populations, so new treatments such as medicines are of paramount importance, as they are more accessible to the broader population.